ByTrending Posts
Will Roche’s 2025 Earnings Reset the Narrative for…
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
Why Is Roche Returning to China for Its…
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Roche Signals Dual Growth Strategy: Price Reform Alignment…
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
Can Amgen’s Strategic Partnerships Redefine Access and Growth…
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and…
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
Is Novo Nordisk Positioning Cell-Based Therapies as the…
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes…
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
Is Novo Nordisk’s Oral Wegovy Off to a…
23 January 2026 Executive Summary Novo Nordisk’s newly launched oral Wegovy weight-loss therapy has recorded a robust debut,…
Roche Doubles Down on U.S. Biomanufacturing: $2 Billion…
23 January 2026 Executive Summary Roche’s Genentech unit announced a major expansion of its biomanufacturing facility in Holly…
Trending Posts
Latest Stories
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with…
Obesity Market Poised for $200B+ US Breakthrough by 2040: A Strategic Gold Rush
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040…
AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked by Biology’s Chaos?
AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment…
Gallery
